Alain H. Rook, MD, Professor of Dermatology, University of Pennsylvania, Perelman School of Medicine provides part one of a three part overview of treatments for cutaneous lymphoma.
Alain H. Rook, MD, Professor of Dermatology, University of Pennsylvania, Perelman School of Medicine provides part one of a three part overview of treatments for cutaneous lymphoma.
Magrolimab Plus Rituximab/Chemo Delivers Responses in Relapsed/Refractory DLBCL
February 3rd 2023At 11.3 months of follow-up, magrolimab, rituximab, gemcitabine, and oxaliplatin yielded an overall response rate of 51.5%, including a complete response rate of 39.4%, among patients with relapsed or refractory diffuse large B-cell lymphoma.
Real-World Data Confirm Ide-cel Safety and Efficacy for Patients With Multiple Myeloma
February 2nd 2023Although most patients in the real-world setting would not have met the clinical trial eligibility criteria, the efficacy and safety outcomes with idecabtagene vicleucel were similar for both sets of patients with multiple myeloma.
FDA Approves Zanubrutinib for CLL/SLL
January 19th 2023The FDA has approved zanubrutinib for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The prescribing label comes with warnings for hemorrhage, infections, cytopenias, second primary malignancies, and cardiac arrythmias.
Switch Maintenance Regimens Demonstrate Similar Efficacy for Patients with RAS Wild-Type mCRC
ASH Data Offer Treatment Direction for Oncology Nursing Professionals
HRQOL Analysis Favors Tislelizumab Over Sorafenib in Hepatocellular Carcinoma
Encorafenib Triplet Elicits Antitumor Activity in BRAF V600E+ mCRC
2 Clarke Drive
Cranbury, NJ 08512